TY - JOUR
T1 - Surface-ehanced Raman sattering (SERS) spectroscopy technique for lactic acid in serum measurement
AU - Chiang, Hui Hua Kenny
AU - Hsu, Po Hsiang
PY - 2005
Y1 - 2005
N2 - Highly sensitive measurement of biomolecules is very important in clinical diagnosis and biomedical sensing. Spectroscopic methods have played important roles in biomedical sensing system developments. Recent development in surface enhanced Raman scattering (SERS) method has greatly enhanced the weak Raman signals of biomolecules and has provided great potentials for real time measurement of biomolecules of body fluid. In addition, Raman measurement has the advantage of not requiring extrinsic fluorescent marker for labeling purpose. In this study, we have pioneered in the development of SERS spectroscopic measurement technique for serum lactic acid, which is one of the most important metabolic parameter in blood. We have fabricated Ag colloidal nanoparticles to enhance the weak Raman signal of lactic acid in serum. The diameter of the Ag nanoparticle is 20 nm, the nanoparticles concentration is 109particles/ml. We have observed the SERS characteristic peak of lactic acid at 1285-1480cm-1 under 632.8 nm HeNe laser excitation. We have demonstrated the measurement of the lactic acid in filtered serum in the physiological concentration range 5×10-3-22×10 -3mole/L, which is hundred times lower than the detectible range using traditional Raman approach. The serum samples with were measured in a specially designed reflector type sample holder to form a multiple reflection of excitation laser through the sample, between a reflector and a notch filter. In conclusion, this research demonstrates the feasibility of using Ag SERS technique for measuring the lactic acid at physical concentration and establishes the platform technique for human body fluid measurements.
AB - Highly sensitive measurement of biomolecules is very important in clinical diagnosis and biomedical sensing. Spectroscopic methods have played important roles in biomedical sensing system developments. Recent development in surface enhanced Raman scattering (SERS) method has greatly enhanced the weak Raman signals of biomolecules and has provided great potentials for real time measurement of biomolecules of body fluid. In addition, Raman measurement has the advantage of not requiring extrinsic fluorescent marker for labeling purpose. In this study, we have pioneered in the development of SERS spectroscopic measurement technique for serum lactic acid, which is one of the most important metabolic parameter in blood. We have fabricated Ag colloidal nanoparticles to enhance the weak Raman signal of lactic acid in serum. The diameter of the Ag nanoparticle is 20 nm, the nanoparticles concentration is 109particles/ml. We have observed the SERS characteristic peak of lactic acid at 1285-1480cm-1 under 632.8 nm HeNe laser excitation. We have demonstrated the measurement of the lactic acid in filtered serum in the physiological concentration range 5×10-3-22×10 -3mole/L, which is hundred times lower than the detectible range using traditional Raman approach. The serum samples with were measured in a specially designed reflector type sample holder to form a multiple reflection of excitation laser through the sample, between a reflector and a notch filter. In conclusion, this research demonstrates the feasibility of using Ag SERS technique for measuring the lactic acid at physical concentration and establishes the platform technique for human body fluid measurements.
KW - Ag colloidal nanoparticles
KW - Lactic acid
KW - Surface-Enhanced Raman spectroscopy (SERS)
UR - http://www.scopus.com/inward/record.url?scp=31844432383&partnerID=8YFLogxK
U2 - 10.1117/12.618127
DO - 10.1117/12.618127
M3 - Conference article
AN - SCOPUS:31844432383
SN - 0277-786X
VL - 5927
SP - 1
EP - 8
JO - Proceedings of SPIE - The International Society for Optical Engineering
JF - Proceedings of SPIE - The International Society for Optical Engineering
M1 - 59271Z
T2 - Plasmonics: Metallic Nanostructures and Their Optical Properties III
Y2 - 31 July 2005 through 3 August 2005
ER -